Medical - Pharmaceuticals
Compare Stocks
2 / 10Stock Comparison
PETS vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
PETS vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Pharmaceuticals | Medical - Equipment & Services |
| Market Cap | $48M | $6.63B |
| Revenue (TTM) | $195M | $2.35B |
| Net Income (TTM) | $-55M | $128M |
| Gross Margin | 29.9% | 69.7% |
| Operating Margin | -11.1% | 4.6% |
| Forward P/E | — | 51.5x |
| Total Debt | $996K | $1.12B |
| Cash & Equiv. | $55M | $229M |
PETS vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| PetMed Express, Inc. (PETS) | 100 | 6.4 | -93.6% |
| Hims & Hers Health,… (HIMS) | 100 | 258.4 | +158.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PETS vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PETS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.25, yield 0.4%
- Lower volatility, beta 1.25, Low D/E 1.2%, current ratio 1.26x
- Beta 1.25, yield 0.4%, current ratio 1.26x
HIMS is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs PETS's -47.8%
- 59.0% revenue growth vs PETS's -17.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs PETS's -17.2% | |
| Quality / Margins | 5.5% margin vs PETS's -28.2% | |
| Stability / Safety | Beta 1.25 vs HIMS's 2.40, lower leverage | |
| Dividends | 0.4% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | -36.5% vs HIMS's -51.0% | |
| Efficiency (ROA) | 6.0% ROA vs PETS's -54.9%, ROIC 10.7% vs -3.1% |
PETS vs HIMS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS is the larger business by revenue, generating $2.3B annually — 12.0x PETS's $195M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to PETS's -28.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $195M | $2.3B |
| EBITDAEarnings before interest/tax | -$14M | $164M |
| Net IncomeAfter-tax profit | -$55M | $128M |
| Free Cash FlowCash after capex | -$34M | $73M |
| Gross MarginGross profit ÷ Revenue | +29.9% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -11.1% | +4.6% |
| Net MarginNet income ÷ Revenue | -28.2% | +5.5% |
| FCF MarginFCF ÷ Revenue | -17.4% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.5% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.7% | -27.3% |
Valuation Metrics
PETS leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $48M | $6.6B |
| Enterprise ValueMkt cap + debt − cash | -$5M | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -7.67x | 50.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 51.51x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -0.98x | 42.68x |
| Price / SalesMarket cap ÷ Revenue | 0.21x | 2.82x |
| Price / BookPrice ÷ Book value/share | 0.56x | 12.25x |
| Price / FCFMarket cap ÷ FCF | — | 89.61x |
Profitability & Efficiency
Evenly matched — PETS and HIMS each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-128 for PETS. PETS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), PETS scores 5/9 vs HIMS's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -127.8% | +23.7% |
| ROA (TTM)Return on assets | -54.9% | +6.0% |
| ROICReturn on invested capital | -3.1% | +10.7% |
| ROCEReturn on capital employed | -1.7% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 2.07x |
| Net DebtTotal debt minus cash | -$54M | $892M |
| Cash & Equiv.Liquid assets | $55M | $229M |
| Total DebtShort + long-term debt | $996,000 | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -73.26x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $1,792 for PETS. Over the past 12 months, PETS leads with a -36.5% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs PETS's -42.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -30.3% | -23.2% |
| 1-Year ReturnPast 12 months | -36.5% | -51.0% |
| 3-Year ReturnCumulative with dividends | -80.5% | +116.6% |
| 5-Year ReturnCumulative with dividends | -82.1% | +137.6% |
| 10-Year ReturnCumulative with dividends | -47.8% | +161.9% |
| CAGR (3Y)Annualised 3-year return | -42.0% | +29.4% |
Risk & Volatility
PETS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PETS is the less volatile stock with a 1.25 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PETS currently trades 53.2% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 2.40x |
| 52-Week HighHighest price in past year | $4.32 | $70.43 |
| 52-Week LowLowest price in past year | $1.57 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +53.2% | +36.4% |
| RSI (14)Momentum oscillator 0–100 | 47.7 | 54.5 |
| Avg Volume (50D)Average daily shares traded | 81K | 34.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
PETS is the only dividend payer here at 0.38% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $29.67 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.01 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% |
HIMS leads in 2 of 6 categories (Income & Cash Flow, Total Returns). PETS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
PETS vs HIMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PETS or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -17. 2% for PetMed Express, Inc. (PETS). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PETS or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -82. 1% for PetMed Express, Inc. (PETS). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus PETS's -47. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PETS or HIMS?
By beta (market sensitivity over 5 years), PetMed Express, Inc.
(PETS) is the lower-risk stock at 1. 25β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 92% more volatile than PETS relative to the S&P 500. On balance sheet safety, PetMed Express, Inc. (PETS) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PETS or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -17. 2% for PetMed Express, Inc. (PETS). On earnings-per-share growth, the picture is similar: PetMed Express, Inc. grew EPS 18. 9% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PETS or HIMS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -2. 8% for PetMed Express, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -0. 7% for PETS. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PETS or HIMS?
In this comparison, PETS (0.
4% yield) pays a dividend. HIMS does not pay a meaningful dividend and should not be held primarily for income.
07Is PETS or HIMS better for a retirement portfolio?
For long-horizon retirement investors, PetMed Express, Inc.
(PETS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PETS: -47. 8%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PETS and HIMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PETS is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.